Merck announced new data for Alzheimer’s candidates MK-2214 and MK-1167 at the Clinical Trials on Alzheimer’s Disease conference and received FDA Fast Track designation for MK-2214.

SCIEX announces the localization of its flagship mass spectrometry platforms in China, marking a major advance for pharmaceutical R&D and manufacturing capabilities in the region.

The European Union is advancing new legislation to reduce medicine shortages by incentivising onshore drug and API manufacturing and introducing 'Buy European' public procurement priorities.

A coordinated FDA initiative and international coalition are advancing non-animal methods in preclinical drug development, accelerating adoption industry-wide.

Telix Pharmaceuticals inaugurated its first Asia-Pacific cyclotron manufacturing facility in Yokohama, Japan, boosting regional radiopharmaceutical production capacity.

Alvotech and Advanz Pharma secured European Economic Area approval for Gobivaz®, a biosimilar to Simponi® (golimumab), expanding access to advanced treatments for immune-mediated diseases.

Novartis received FDA approval for Itvisma, a gene replacement therapy for spinal muscular atrophy, expanding access to a broader patient group in the US.

China launches a dual-track payment model introducing the Commercial Health Insurance Innovative Drug List (CHIIDL), opening new market access and reimbursement channels for innovative medicines.

Europe's leading pharma lab event commences in Düsseldorf, bringing together industry and regulators to advance laboratory analytics, automation, and GMP compliance.

Multi-billion dollar AI drug discovery partnerships and Abbott’s $21B acquisition of Exact Sciences reshape the American pharmaceutical tech landscape.